In a letter to PM Modi on Tuesday, Prime Minister Roosevelt Skerrit of the Dominican Republic, has also requested for inoculation, signally that the demand for Indian jabs has acquired a transcontinental appeal. "As we enter 2021 and persevere in our fight against Covid-19, Dominica's population of 72,100 is in urgent need of enough doses of the Oxford-AstraZeneca vaccine. I, therefore, request, with great humility and respect, that you assist us by donating the doses we need to make our population safe (optimally 70,000 first and second doses)," wrote Skerrit.
In other parts of Latin America, Brazil, which has the second highest number of coronavirus cases in the world next only to the United States, has sent a special plane to pick up Indian vaccines from Pune.
A Brazilian plane is expected to fly the first 2 million doses of a Covid-19 vaccine purchased by the government's Fiocruz biomedical institute.
According to a Reuters report from Sao Paulo, Health Minister Eduardo Pazuello said the documentation is ready for bringing the AstraZeneca-Oxford University vaccine being produced at the Serum Institute of India.
Brazil's Anvisa has scheduled a meeting for next Sunday to decide on the emergency use of the vaccine developed by AstraZeneca and Oxford as well as one by developed by China's Sinovac Biotec.
Meanwhile the Bolivian government had also signed a contract with India's Serum Institute for the supply of 5 million doses of AstraZeneca's Covid-19 vaccine.
President Luis Arce said that combined with a recent deal to buy 5.2 million Sputnik V vaccine doses from Russia, Bolivia now expected to be able to inoculate all of its vaccinable population.
The sources said that in tune with Prime Minister Modi's message that India's vaccine approach are intended to heal humanity, India would not be averse to provide vaccines to Pakistan, as part of a drive to eliminate the virus globally.
And in the course of time if the Chinese vaccine does not work, India would not hesitate to supply jabs to Beijing as well. The sources pointed out that India's vaccine exports to China may go a long way in addressing India's adverse trade balance with the Middle Kingdom.
So far, China's vaccine has shown patchy results. For instance, after Thailand has discovered that the efficacy of the two million doses of the Chinese Sinovac Biotech Covid-19 vaccine, has dropped dramatically.
The Bangkok Post said that the Thai Ministry of Public Health has requested further information about the vaccine it has ordered from China following a report "it might not be as effective as first thought" even as it goes ahead with its plan to receive and administer the vaccine from Sinovac Biotech.
"We are asking for information directly from Sinovac, so we are waiting for their response to get all the facts," Supakit Sirilak, Thailand's Director-General of Medical Science Department, was quoted as saying by the newspaper.
Singapore too has confirmed that the vaccine developed by China's Sinovac Biotech will have to go through regulatory scrutiny and authorisation by the country's Health Sciences Authority (HSA) before being rolled out for the public.
"We will go through the data carefully when it comes, rather than depending on reported numbers. It's better to rely on official data that we receive from Sinovac itself," said Singapore's Health Minister Gan Kim Yong according to a report in The Straits Times.
(This content is being carried under an arrangement with indianarrative.com)
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.